摘要
目的通过研究野鸢尾黄素对体内及体外炎症模型的影响进一步证实其抗炎作用。方法体内模型选用琼脂诱导的大鼠肉芽肿炎症模型,将琼脂植入大鼠体内,引发炎症。分别应用高、中、低(80,40,20mg·kg^(-1))三种不同的剂量的野鸢尾黄素进行干预,并观察测定琼脂肉芽肿的重量,通过称取琼脂块湿重来考察野鸢尾黄素在体内的抗炎作用。体外模型选用脂多糖(LPS)诱导A549细胞,建立细胞炎症反应模型。用不同浓度的野鸢尾黄素(154.0,77.00,38.50μg·mL^(-1))进行干预,用MTT法测定不同浓度野鸢尾黄素对A549细胞活力的影响;ELISA法检测细胞上清液中炎症因子IL-6的含量。结果在体内实验中:与空白模型组比较,野鸢尾黄素高、中、低剂量组均抑制了大鼠肉芽肿的增生,其中低、中剂量组显示出显著差异(P<0.01),而高剂量组亦差异较明显(P<0.05),差异存在统计学意义;体外实验中:野鸢尾黄素各剂量组对细胞活力均无明显影响;LPS组IL-6水平较正常细胞组升高(P<0.01);野鸢尾黄素能显著抑制炎症因子IL-6的生成。结论野鸢尾黄素无论在体内还是体外炎症模型中均存在一定的抗炎作用。
Objective To study the anti-inflammatory effect of irigenin on the inflammatory model in vivo and in vitro. Methods In vivo model we selected granuloma inflammation model in rats induced by agar.Three different doses of irigenin(80 mg·kg^(-1),40 mg·kg^(-1),20 mg·kg^(-1)) were used for intervention respectively, and the weight of agar granuloma was observed and measured. The wet weight of agar was weighed to investigate the content of irigenin in vivo anti-inflammatory effect. In vitro, we used lipopolysaccharide(LPS) to induce A549 cells and established the cell inflammatory response model. Different concentrations of irigenin(154.0μg·ml^(-1), 77.00μg·ml^(-1), 38.50μg·ml^(-1)) were used for intervention, and a blank group was established. We used MTT method to determine the effect of different concentrations of irigenin on the activity of A549 cells;ELISA method was used to detect the content of inflammatory factor IL-6 in the supernatant of cells.Results In vivo experiment, the level of IL-6 in LPS group was higher than that in normal cells(P< 0.01), and irigenin could significantly inhibit the production of inflammatory factor IL-6;In vitro experiment: the proliferation of granuloma was inhibited in high, middle, and low dose groups, among significant difference between low and medium dose groups(P<0.01), and a significant difference was found in high dose group(P<0.05). Conclusion Irigenin has a good anti-inflammatory effect both in vivo and in vitro.
作者
左芳
刘晶
邹桂欣
王光函
张颖
尤献民
李国信
ZUO Fang;LIU Jin;ZOU Gui-xin;WANG Guang-han;ZHANG Ying;YOU Xian-min;LI Guo-xin(Liaoning University of Traditional Chinese Medicine,Shenyang Liaoning 110847 China;Liaoning Academy of Traditional Chinese Medicine,Shenyang Liaoning 110034 China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2021年第7期1581-1584,共4页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(81273927)
国家“十三五”重大新药创制项目(2017ZX09301019)
辽宁省博士科研启动基金计划项目(2019-BS-143)。
